Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (VIR) pioneers immunology solutions targeting complex infectious diseases through innovative platforms including antibody therapies, T cell engineering, and siRNA technology. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory milestones.
Access authoritative updates on VIR's research pipeline, financial performance announcements, and scientific breakthroughs in infectious disease management. Our curated collection ensures transparent access to press releases spanning clinical trial progress, collaborative initiatives, and patent filings.
Key updates include advancements in hepatitis B/HIV therapies, influenza A research, and platform technology licensing agreements. Bookmark this page to efficiently monitor VIR's contributions to biotechnology and its evolving position in global health innovation.
Vir Biotechnology announced that CEO George Scangos, Ph.D., will engage in a virtual fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 8:45 am PT / 11:45 am ET. The session will be accessible via live webcast in the Investors section of the Vir website, with an archived version available for 30 days post-event. Vir Biotechnology focuses on treating serious infectious diseases using advanced immunologic technologies, with ongoing projects targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology announced promising results for VIR-7831, an investigational monoclonal antibody targeting SARS-CoV-2. New preclinical data show VIR-7831 maintains its neutralizing activity against the L452R mutation found in the California variant. While the California variant reduces the neutralization potency of plasma from vaccinated individuals, VIR-7831 remains effective, highlighting its potential to combat current and future variants. The company aims to expedite VIR-7831's availability for patients amidst rising variant concerns.
Eli Lilly, Vir Biotechnology, and GlaxoSmithKline announced encouraging results from the Phase 2 BLAZE-4 trial, demonstrating a 70% reduction in high viral load for COVID-19 patients treated with bamlanivimab and VIR-7831 compared to placebo. The trial met its primary endpoint with a p-value of <0.001. No COVID-19 related hospitalizations or deaths occurred by day 29 in either treatment arm. Despite these promising data, both drugs are investigational and not yet FDA-approved. Discussions with regulatory bodies are ongoing to expedite availability.
Eli Lilly, Vir Biotechnology, and GlaxoSmithKline announced promising topline results from the Phase 2 BLAZE-4 trial, showing that the combination of bamlanivimab and VIR-7831 significantly reduced high viral loads in low-risk COVID-19 patients by 70% at day 7 compared to placebo. No related hospitalizations or deaths occurred by day 29. Preclinical data suggest the combination can combat resistant SARS-CoV-2 variants. An Emergency Use Authorization application for VIR-7831 has been submitted to the FDA, aiming to expedite its availability for COVID-19 treatment.
Vir Biotechnology and GlaxoSmithKline have applied for Emergency Use Authorization (EUA) from the FDA for VIR-7831, a dual-action monoclonal antibody for adults and adolescents with mild-to-moderate COVID-19 at risk for hospitalization. The application is supported by interim data from the Phase 3 COMET-ICE trial, showing an 85% reduction in hospitalization or death compared to placebo. An Independent Data Monitoring Committee halted further enrollment due to significant efficacy. The companies are also pursuing regulatory discussions in Europe for broader access to this treatment.
Vir Biotechnology and GSK announced that the Independent Data Monitoring Committee recommended stopping the Phase 3 COMET-ICE trial early due to an impressive 85% reduction in hospitalization or death for patients receiving VIR-7831 compared to placebo. Following this, they plan to seek Emergency Use Authorization in the U.S. and other countries. Additionally, in vitro studies show that VIR-7831 retains effectiveness against major COVID-19 variants. The trial involved 583 patients, with ongoing follow-up to gather more data on safety and efficacy.
Vir Biotechnology and GlaxoSmithKline announced an update on their COVID-19 treatment, VIR-7831, during the NIH's ACTIV-3 trial. Although VIR-7831 initially met criteria to advance, concerns regarding its efficacy led to a recommendation to close its enrollment. The Data and Safety Monitoring Board found no safety issues but noted uncertainties about patient benefit. The companies aim to further evaluate VIR-7831's potential while upcoming data from the COMET-ICE trial is anticipated. VIR-7831 is designed to block viral entry and clear infected cells, potentially effective against emerging variants.
Vir Biotechnology (Nasdaq: VIR) reported strong progress in its development pipeline, with six molecules targeting serious infectious diseases. Total revenues for 2020 reached $76.4 million, a significant increase from $8.1 million in 2019, primarily driven by a collaboration with GSK. The company anticipates key data from Phase 3 trials for its monoclonal antibodies against COVID-19 (VIR-7831 and VIR-7832) in early 2021. However, the net loss for Q4 2020 was $105.6 million, up from $63.8 million in Q4 2019, reflecting increased R&D and administrative expenses.
Vir Biotechnology and GlaxoSmithKline have expanded their collaboration to develop monoclonal antibodies for influenza and other respiratory viruses. GSK will invest $120 million and make an upfront payment of $225 million to accelerate research on VIR-2482, an investigational antibody designed for universal prophylaxis against influenza A. This collaboration also includes exploration for additional antibody candidates targeting non-influenza pathogens. The agreement hinges on customary regulatory conditions.
Vir Biotechnology (Nasdaq: VIR) will release its fourth-quarter and full-year financial results for 2020 on February 25, 2021. The corporate update is set to follow after market close and will be available on the company’s website under the Investors section.
Vir is focused on treating serious infectious diseases through innovative immunology technologies and has a pipeline addressing COVID-19, hepatitis B, influenza A, and HIV.
